17.04.18 20:16

First human volunteer recruited: Start of Phase I-study for Alzheimer's therapy

The Phase I clinical study, in which the new Alzheimer's drug candidate PRI-002 is being tested for the first time in humans, has now officially started in Vienna. On Monday, PRI-002 was administered to the first healthy volunteer. The study will evaluate the safety and tolerability of the oral dosage form of PRI-002 in healthy volunteers. Prof. Dieter Willbold, developer of PRI-002 and director of the Institut für Physikalische Biologie, was present in Vienna while the Phase I study started.

Responsible for the content: E-MailStabsstelle Presse und Kommunikation